Table 4.
Univariate analysis of factors related to mPFS and mOS of patients in this study (N=80).
| Characteristics | mPFS (months) | P value | mOS (months) | P value |
|---|---|---|---|---|
| Age (years) | ||||
| ≥45 | 5.50 | 10.2 | ||
| <45 | 6.80 | 0.613 | 13.4 | 0.395 |
| Pathological type | ||||
| Squamous cell | 6.10 | 11.3 | ||
| Adenocarcinoma | 3.90 | 0.639 | 7.60 | 0.791 |
| ECOG PS | ||||
| 0 | 7.30 | 13.4 | ||
| 1 | 5.90 | 0.562 | 11.2 | 0.823 |
| Size of primary tumor (cm) | ||||
| ≥5 | 6.70 | 13.2 | ||
| <5 | 6.10 | 0.115 | 11.2 | 0.895 |
| First-line chemotherapy with bevacizumab | ||||
| Yes | 6.30 | 11.3 | ||
| No | 4.45 | 0.400 | 8.00 | 0.157 |
| Location of metastatic tumors | ||||
| Lung | 8.30 | 15.3 | ||
| Others | 6.10 | 0.931 | 11.3 | 0.130 |